Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

Published 12 hours ago

Source: rss.nytimes.com

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

Enbrel, a once-a-week injection used to treat a variety of autoimmune conditions, first arrived on the market nearly 30 years ago.

Categories

Prices (Fares, Fees and Rates)Inventions and PatentsDrugs (Pharmaceuticals)Health Insurance and Managed CLaw and LegislationRegulation and Deregulation ofState LegislaturesAutoimmune DiseasesInsuranceGeneric Brands and Products

Read Original Article

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

Categories

Related Articles from rss.nytimes.com

Is It ‘Subsidizing the Rich’ to Make Buses and Child Care Free for All?

The Death of Democracy Is Happening Within You

Bay Area Protesters Try to Block Base Entrance Before Immigration Operation

Trump Opens ANWR to Oil Drilling

Archbishop of U.S. Anglican Church Is Accused of Sexual Harassment

Virginia Democrats Plan to Redraw House Maps in Redistricting Push